NI, Yong,PARIKH, Bhavnish,YELESWARAM, Krishnaswamy,ERICKSON-VIITANEN, Susan,WILLIAMS, William V.
申请号：
AU2020201011
公开号：
AU2020201011A1
申请日:
2020.02.12
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020201011A120200305.pdf#####ABSTRACT The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.1/4 1000 -o-25 mg IR -- 25 mg SR-1 -+-25 mg SR-2 ac100 O 0 (D O 2. 10 0 1 - . . , . . , . . , . . , . . , . 0 6 12 18 24 30 36 Time (h) FIG. 1
